Cannabis and Hemp Industry Investment News

Cannabis Industry Press Releases and News Articles from the best investment journalist in the industry. Stay updated on all cannabis investment news from every online source, on MjInvest.com

Lexaria Bioscience wins order commitments for 4.4M CBD servings of its patented DehydraTECH-enabled CBD powders

Lexaria also has received verbal requests from existing licensees to prepare its facilities to produce at least 56 million servings during the calendar year 2021

DehydraTECH masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform

Lexaria Bioscience Corp ()(), a global innovator in drug delivery platforms, announced Wednesday it has purchase-order commitments for about 4.4 million CBD servings of its patented DehydraTECH-enabled CBD powders.

In a statement, the company added that the CBD servings were processed during its fiscal first quarter of 2021, which ends November 30, 2020.

Lexaria also said it has received verbal requests from existing licensees to prepare its facilities to produce at least 56 million servings during the calendar year 2021. 

READ: Lexaria Bioscience wins ninth US patent as it expands patent portfolio

So far, about 1.2 million CBD servings already have been processed in fiscal 4Q ended August 31, 2020, along with some 700,000 CBD servings during the company's fiscal Q3 ended May 31, 2020. A serving generally ranges from 10 milligrams (mg) to 20mg of CBD each, utilizing the company's DehydraTECH patented processes.

Continue reading
  8 Hits

Lexaria Bioscience wins ninth US patent as it expands patent portfolio

The new patent protects the use of Lexaria's DehydraTECH technology together with cannabinoids, nicotine and nonsteroidal anti-inflammatory drugs

Lexaria currently has 17 patents, with eight in Australia and the nine in the US, along with roughly 60 patent applications pending globally

Lexaria Bioscience Corp () (), a global innovator in drug delivery platforms, has received its ninth US patent.

In a statement Tuesday, the company said the new patent provides patent claims that protect the use of its DehydraTECH technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix-and-serve beverage formats. 

The patent is entitled "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” -- and signifies another addition to Lexaria's first patent family.

READ: Lexaria Bioscience says it supports DehydraTECHTM licensee Boldt Runners' corporate growth initiatives

Lexaria said it has also responded to patent office queries in Europe, India, Mexico, Australia, US, Japan and Canada in recent weeks. However, the company does not expect all its applications to be successful but is optimistic of additional patent grants in some of these locations soon.

Continue reading
  10 Hits

Canntab Therapeutics achieves major milestone receiving first U.S. patent for multilayer tablets

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CEO Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has secured protection for their intellectual property receiving a U.S. patent for “Modified Release Multi-Layer Tablet Cannabinoid Formulations.”

Latowsky talks about what that means for the company and moving forward and how they hope to now make a major push to monetize that IP.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  10 Hits

Canntab Therapeutics wins its first US patent covering its multi-layer tablet cannabinoid formulations

The new patented tablets consist of both Instant Release and Extended Release formulations with THC and CBD as well as a variety of terpenes and other cannabinoids

Canntab has filed applications for 13 patents in Canada and the US that cover a range of processes and formulations to create its oral-delivery hard tablets

Canntab Therapeutics Limited () (OTCQB:CTABF) said Monday it has won a first US patent covering its multi-layer (bi-layer) tablet cannabinoid formulations.

The new patented tablets consist of both Instant Release (IR) and Extended Release (XR) formulations with THC, CBD, and a variety of Terpenes and other Cannabinoids found in full-spectrum Cannabis and Hemp oil resin, the company said. 

"This is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace which will support a faster revenue stream as we begin production and distribution in the immediate future,” Canntab CEO Larry Latowsky said in a statement.

READ: Canntab Therapeutics spends C$1.3M on cannabis processing equipment in two all-stock deals

“This is the first patent that was issued to date out of the 13 that we have applied for, and will be leveraged to solidify Canntab's position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids,” Latowsky added.

Continue reading
  10 Hits

Lexaria Bioscience says it supports DehydraTECHTM licensee Boldt Runners' corporate growth initiatives

Boldt Runners' Cannadips CBD is the leading CBD oral pouch brand in America, and Lexaria's fast-acting absorption technology is inside every tin

Boldt Runners is preparing for strong growth through its recent executive appointments, financing, and sales channel expansion

Lexaria Bioscience Corp () () said Wednesday it supports the corporate growth initiatives underway by its DehydraTECHTM licensee Boldt Runners Corporation, owners of the Cannadips CBD brand.

Cannadips CBD is the original and leading CBD oral pouch brand in America, and Lexaria said its fast-acting absorption technology is inside every tin. 

Lexaria added that Boldt Runners is preparing for strong growth through its recent executive appointments, financing, and sales channel expansion. The combination is expected to lead to a large increase in sales volumes over the next 12 months.

READ: Lexaria Bioscience strikes R&D agreement with British American Tobacco to investigate its technology for potential use in nicotine products

The company said Peter Diatelevi has been appointed as Boldt Runners' new chief executive officer. He brings more than two decades of experience with Altria Corp, leading field sales and sales operations in a number of roles including vice president of sales operations.

Continue reading
  18 Hits

Innocan Pharma says clinical trials demonstrate the effectiveness of SHIR line of CBD skincare products

Results indicated significant hydration increases for each two-, four-, eight, and 24-hour period after application

The SHIR facial serum contains 300 milligrams of CBD

Innocan Pharma Corporation () said Tuesday that clinical studies have demonstrated the effectiveness of the firm’s SHIR CBD facial serum on skin hydration.

The study looked at the impact of SHIR, which contains 300 milligrams of CBD, on hydration levels by measuring the skin capacitance periodically up to 24 hours after the serum was applied.

Results indicated significant hydration increases for each two-, four-, eight, and 24-hour period after application, according to a release from Innocan. In addition, the serum was well tolerated with no uncomfortable symptoms reported by participants.

READ: Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland

All of the SHIR Derma Cosmetic products tested to date have demonstrated to be non-irritating in clinical testing, according to Israel-based Innocan.

Continue reading
  20 Hits

EXMceuticals now '100% focused on being a refining bioscience business in Portugal'

Inc's () Jonathan Summers speaks to Proactive London's Katie Pilbeam about their cannabis research and development.

Summers explains that the company has recently transitioned from being active in Africa to focusing their attentions solely onto Portugal.

The company recently announced securing a COVID-19 R&D-focused grant from the European Union and the Portuguese Government to accelerate their operations on creating a disposable filter for a mask.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Continue reading
  16 Hits

EXMceuticals receives coronavirus research grant from EU and Portuguese government

The company's consortium in Portugal will use the funds to study and develop disinfectants to combat SARScoV-2, the virus that causes coronavirus (COVID-19)

The €302,000 grant has been awarded by the European Regional Development Fund and the Portuguese government

Inc () (FRA:A2PAW2) said it has secured a coronavirus (COVID-19) research & development (R&D) focused grant from the European Union (EU) and the Portuguese government in what it said was a “landmark event” for the company.

The biosciences group, which specializes in unique cannabinoid formulations, said a consortium led by EXMceuticals Portugal Lda, operating under the project name ‘BioBlockCOVID’ and consisting of EXMceuticals Portugal Lda, Cosmetek Lda, and the Universidade de Coimbra, has been awarded €302,000 by the European Regional Development Fund (ERDF) and the Portuguese government to study and develop disinfectants to combat SARScoV-2, the virus that causes COVID-19.

READ: EXMceuticals advances R&D operations in Portugal and its efforts to fight coronavirus

The BioBlockCOVID project aims to create functional, natural and innovative biocide formulations that will specifically target and attack the molecules that make up COVID-19. The research will focus on the virucidal action of naturally occurring bioactive compounds from the cannabis plant, in addition to others.

EXMceuticals said the award comes from a competitive tender opened by the ERDF, which finances two Portuguese funds named Programa Operacional Competitividade e Internacionalização and Programa Operacional Regional de Lisboa, to support companies and R&D entities based in Portugal. The grant aims to create an incentive system for R&D activities and investment in testing and optimization infrastructure of relevant products in combating COVID-19.

Continue reading
  27 Hits

Innocan Pharma says Mackie Research sales group issues Enterprise report on its potential clinical, licensing and commercial catalysts

viewInnoCan Pharma

Analyst Toby Ma highlighted the Israeli company’s potential clinical, licensing and commercial catalysts

Innocan is developing a revolutionary injectable CBD delivery system

Corporation () announced Thursday that Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on the company.

The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action.

READ: InnoCan Pharma collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes

In a statement, Innocan said Mackie Research analyst Toby Ma highlighted the Israeli company’s potential clinical, licensing and commercial catalysts:

Continue reading
  35 Hits

Lexaria Bioscience signs R&D agreement with British American Tobacco

viewLexaria Bioscience Corp.

Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with British American Tobacco Limited. That company has products sold in over 11 million locations across more than 180 countries.

Bunka telling Proactive the deal is for research and development that will investigate Lexaria's technology for potential use in nicotine products. All costs of the research will be covered by British American Tobacco.

CSE:LXX

Market: CSE
Market Cap: $37.63 m
Follow

View company profile

Continue reading
  42 Hits

Lexaria Bioscience strikes R&D agreement with British American Tobacco to investigate its technology for potential use in nicotine products

Lexaria said the agreement does not contemplate the development of oral nicotine consumer products in North America

Lexaria Bioscience Corp () () announced Monday that it has entered into a research and development agreement with British American Tobacco Limited (BAT) to investigate its technology for potential use in nicotine products.

The R&D work under the agreement will be paid for by BAT, Lexaria said in a statement.

"Lexaria is pleased to work with British American Tobacco on these research and development activities," said Lexaria CEO Chris Bunka.

READ: Lexaria Bioscience gets approval for CBD DehydraTECH hypertension study in Europe

Lexaria said the agreement does not contemplate the development of oral nicotine consumer products in North America, given Lexaria's existing relationship with a leading US-based tobacco company.

The agreement is expected to be completed within six months, though provisions exist to extend the agreement if required, Lexaria said. 

Continue reading
  42 Hits

EXMceuticals advances R&D operations in Portugal and its efforts to fight coronavirus

The bioscience company said it has applied for a P2020 research grant under the project name SkanABility for a proof-of-concept study of the biological activity of cannabinoids and terpenes in cosmeceutical applications

EXMceuticals also said it has recently submitted an application to the Portuguese government through the I&D COVID-19 initiative and has begun investigating the virucidal efficacy of cannabis and terpene molecules in combatting the coronavirus

Inc () (FSE:A2PAW2) said it has made advancements in the research & development (R&D) operations at its facility in Lisbon, Portugal.

The bioscience firm, which specializes in unique cannabinoid formulations, said it has applied for a P2020 research grant under the project name SkanABility for a proof-of-concept study of the biological activity of cannabinoids and terpenes in cosmeceutical applications.

READ: EXMceuticals settles $4.6 million loan through share issuance

The project is seeking to demonstrate the commercial viability of cannabis compounds in cosmetic and aromatherapy products, as well as develop sustainable, functional packaging based on biodegradable cannabis materials such as fibers and waxes which will help to extend product shelf-life and preserve formulations and properties.

EXMceuticals noted that SkanABility will develop formulations for different types of cosmetics and aromatherapies such as acne face cleansers, anti-inflammatory and hypoallergenic treatments, and essential oils that the company plans to sell to industrial and pharmaceutical companies through a royalty-based business model.

Continue reading
  39 Hits

Canntab Therapeutics spends C$1.3M on cannabis processing equipment in two all-stock deals

The company is offering more than 2.5 million shares in total at a price of C$0.51 per share

Canntab is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations

Canntab Therapeutics Limited () (OTCQB:CTABF) has reached a pair of binding agreements to buy $1.3 million worth of cannabis processing equipment and leasehold improvements for its Markham, Ontario facility. 

The first deal will see the company pay C$1 million by issuing nearly 2 million shares of stock at a price of C$0.51 per share. The seller of the equipment is CMAX Technologies Inc, a related party of which Canntab CFO Richard Goldstein is the sole director and officer.

A deposit of 200,000 shares will be paid to CMAX within two weeks of the purchase agreement being executed. 

READ: Canntab Therapeutics announces the appointment of Larry Latowsky as its CEO with immediate effect

Additionally, the company has agreed to purchase $300,000 in cannabis processing equipment from Pharmagenerics Solutions Inc, which it will pay for by issuing 588,235 shares at the same C$0.51 price. 

Continue reading
  38 Hits

Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland

The distribution agreement with Cloud 9 Switzerland LLC will see it sell Innocan’s SHIR Beauty and Relief & Go lines in the two countries

The deal marks Innocan's second distribution agreement in Europe

Innocan Pharma Corporation () said Thursday that it inked a deal to distribute its CBD line of beauty and pharmaceutical products in Italy and Switzerland.

The distribution agreement with Cloud 9 Switzerland LLC will see it sell Innocan’s SHIR Beauty and Relief & Go lines in the two countries, according to a release.

Iris Bincovich, Innocan’s CEO, expressed the company’s excitement to see its products distributed in Italy and Switerland.

READ: Innocan Pharma subsidiary inks manufacturing and distribution deal with Calgary cannabis producer Endless Sky

“This is the second distribution agreement we have signed in Europe,” Bincovich said in a statement. “I believe Cloud 9 will provide professional distribution of our SHIR and Relief & Go product lines."

Continue reading
  49 Hits

Canntab Therapeutics announces the appointment of Larry Latowsky as its CEO with immediate effect

Canntab had originally announced that Latowsky would be appointed to the board as executive chairman, however, the board of directors unanimously determined that he would be much more valuable to the company in a full-time role as CEO

eff Renwick, co-founder of Canntab, will assume the role of president and Head of Manufacturing while remaining an integral member of Canntab's board of directors

Canntab Therapeutics Limited () (OTCQB CTABF) (FRA:TBF1.F), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has announced the appointment of Larry Latowsky as its CEO effective immediately.

Originally appointed as an advisor to the company, Canntab said it has been mutually decided that Latowsky's extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the group’s operations and accordingly the board of directors decided to appoint him as CEO.

READ: Canntab Therapeutics eyeing sales of its hard pills this summer as it strikes purchase deal with MediPharm Labs

Canntab had originally announced that Latowsky would be appointed to the board as executive chairman, however, the board of directors unanimously determined that he would be much more valuable to the company in a full-time role as CEO to navigate Canntab's future growth.

It said Jeff Renwick, co-founder of Canntab, will assume the role of president and Head of Manufacturing while remaining an integral member of Canntab's board of directors.

Continue reading
  44 Hits

Innocan Pharma teams up with Endless Sky to manufacturer and distribute its CBD products

viewInnoCan Pharma

Innocan Pharma Corporation () CEO Iris Bincovich and Endless Sky CEO Travis George tells Proactive the two have signed a manufacturing and distribution agreement.

Bincovich says Endless Sky will exclusively distribute Innocan’s CBD products in Canada and manufacture them at its Health Canada-licensed facility in Redvers, Saskatchewan.

In exchange, ESI will pay Innocan Israel a fee per product in addition to royalties based on net sales.

CSE:INNO

Continue reading
  47 Hits

Innocan Pharma subsidiary inks manufacturing and distribution deal with Calgary cannabis producer Endless Sky

ESI will exclusively distribute Innocan’s CBD products in Canada and manufacture them at its facility in Saskatchewan

Innocan’s products include its Relief and Go CBD Spray and Cream as well as the SHIR Eye Serum, Face Cream and Night Cream.

Innocan Pharma Corporation () announced Tuesday that its subsidiary Innocan Israel signed a manufacturing and distribution agreement with Endless Sky Incorporated (ESI), a large-scale cannabis extraction company based in Calgary.

ESI will exclusively distribute Innocan’s CBD products in Canada and manufacture them at its Health Canada-licensed facility in Redvers, Saskatchewan. In exchange, ESI will pay Innocan Israel a fee per product in addition to royalties based on net sales.

Innocan’s products include its Relief and Go CBD Spray and Cream as well as the SHIR Eye Serum, Face Cream and Night Cream.

READ: Innocan Pharma says its SHIR Beauty & Science CBD Derma Cosmetics greenlit to be marketed in European Union

“We believe that Innocan's patent-pending, CBD-integrated products will be some of the highest quality CBD products to enter the market to date,” Endless Sky CEO Travis George said in a statement. “Israel is well known as the global leader in CBD research and Innocan is leveraging that knowledge with a team of proven experts in the cosmetics, healthcare, sports medicine, and wellness markets. The pharmaceutical expertise of Innocan together with Endless Sky's large extraction capacity and manufacturing capabilities will combine to bring top of the line products to market at scale and price points that will allow for wide market access.”

Continue reading
  55 Hits

Innocan Pharma says its SHIR Beauty & Science CBD Derma Cosmetics greenlit to be marketed in European Union

The company said its products have “successfully" passed safety assessment in accordance with European Union cosmetic regulation No 1223/2009

CEO Iris Bincovich said compliance with EU regulation is "a major milestone" for the company, after receiving technical validation from the FDA to market its Relief & Go Pain Relief spray in the US

Innocan Pharma Corporation () announced Thursday that its SHIR CBD Derma Cosmetic product line has received the greenlight to be marketed in the European Union.

The company said its products had “successfully" passed safety assessment in accordance with European Union cosmetic regulation No 1223/2009, and also received a EU Cosmetic Product Safety Report for marketing in the European Union.

According to Innocan, SHIR skincare products combine the benefits of CBD with the most effective ingredients in an “innovative formula” to deliver “visible results.” The SHIR Beauty & science products that are approved for marketing in the Europe include a SHIR CBD+ ANTI-AGING Beauty Sleeping Mask, SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, and SHIR CBD+ ANTI-AGING Facial Serum.

READ: Innocan Pharma says over-the-counter Relief & Go Pain Relief spray wins FDA approval to commence marketing

Continue reading
  66 Hits

InnoCan Pharma CBD delivery approach holds potential to lower costs, broaden treatment options

InnoCan is working on a revolutionary exosome-based technology that targets both central nervous system indications and COVID-19 coronavirus symptoms

CBD is advertised as providing relief for anxiety, depression and post-traumatic stress disorder, among other benefits. Its popularity reflects, in part, that it is positioned as non-psychoactive while still providing access to many aspects of the cannabis plant that are good for human health.

The challenge is to create a more precise and efficient method for delivering CBD into a patient’s body, preferably allowing for synergistic effects and/or controlled release.

(), based in the Israeli tech hub of Herzliya, has found what might be the golden ticket for CBD-integrated pharmaceutical technology in the form of a method to inject CBD into the body.

InnoCan and Ramot, Tel Aviv University’s business engagement centre supporting scientific discovery, are collaborating on a revolutionary exosome-based technology that targets both central nervous system indications and COVID-19 coronavirus symptoms, as CBD-loaded exosomes have the potential to provide anti-inflammatory properties to help infected lung cells recover. Public Entrepreneur spoke with InnoCan Chief Executive Officer Iris Bincovich recently about this project and other exciting directions the company’s technologies are taking.

Continue reading
  51 Hits

EXMceuticals settles $4.6 million loan through share issuance

viewEXMceuticals

CEO Jonathan Summers acquired 11.3 million shares by way of a private placement, representing around 16.4% of the Vancouver-based company

The shares were acquired at a price of C$0.20 per share

Inc () said it has settled a C$4.6 million loan by issuing just over 23 million shares of the bio-science company.

As part of the loan settlement, CEO Jonathan Summers acquired 11.3 million shares by way of a private placement, representing around 16.4% of the Vancouver-based company.

Summers now owns around 16.5% of EXMceuticals’ 68.8 million outstanding shares on an undiluted basis and just over 18.4 million or 24.3% on a partially diluted basis.

Continue reading
  56 Hits